276. Achondroplasia Clinical trials / Disease details

Clinical trials : 46 / Drugs : 29 - (DrugBank : 6) / Drug target genes : 5 - Drug target pathways : 30

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-002954-21-FR (EUCTR)	06/05/2020	20/01/2020	A study to evaluate Infigratinib in children with Achondroplasia	Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2 - PROPEL 2	Achondroplasia in Children MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Infigratinib phosphate Product Code: BGJ398 (also known as BBP-831) INN or Proposed INN: INFIGRATINIB	QED Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	United States;France;Canada;Spain;Australia;United Kingdom
2	EUCTR2019-002954-21-GB (EUCTR)	31/03/2020	13/05/2020	A study to evaluate Infigratinib in children with Achondroplasia	Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2 - PROPEL 2	Achondroplasia in Children MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Infigratinib phosphate Product Code: BGJ398 (also known as BBP-831) INN or Proposed INN: INFIGRATINIB	QED Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	78	Phase 2	United States;France;Canada;Spain;Australia;United Kingdom